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Background: Gallstone disease (GSD) is a common gastrointestinal disorder throughout the world. The authors
explored the incidence of GSD in Taiwan and its condition-associated predictive factors.
Methods: The initial study cohort comprised 2386 healthy adult participants, who were voluntarily admitted to a
teaching hospital for a physical check-up in 2002 in Taipei, Taiwan. After excluding 126 patients who exhibited
prevalent GSD, 2260 non-GSD participants received annual follow-up screenings for GSD until 31 December, 2007.
Of those, 1296 (57.3%) patients were re-examined to collect blood samples and conduct ultrasound sonography.
Results: Among the 1296 participants who exhibited no GSD at the first screening, 23 patients developed GSD
during 3640 person-years of follow-up. The incidence was 0.632% per year (95% CI: 0.292%–2.009%). After
conducting a Cox regression, increased age (50–59 years versus < 40 years, RR = 2.16 [95% CI: 1.09–5.97], 60+ years
versus < 40 years, RR = 3.81 [95% CI: 2.77–8.63]), high body mass index (≥27 kg/m2 versus < 24 kg/m2, RR = 1.64
[95% CI: 1.07–2.98]), high fasting plasma glucose levels (≥126 mg/dL versus < 110 mg/dL, RR = 1.68, 95%
CI: 1.10–3.87), and nonalcoholic fatty liver disease (yes versus no, RR = 1.44, 95% CI: 1.21–1.90) appeared to be
significantly related to developing GSD.
Conclusion: Increased age is a well-established risk factor for developing GSD. The current findings indicated that
high body mass index, elevated fasting plasma glucose levels, and nonalcoholic fatty liver disease were also
associated with GSD.
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Gallstone disease (GSD), a digestive disorder with multi-
factorial origins, is a common gastrointestinal disorder
throughout the world. The third National Health and
Nutrition Examination Survey estimated that 6.3 million
men and 14.2 million women ages 20–74 in the United
States had GSD [1]. Although GSD yields a low mortal-
ity rate, an increased risk of overall mortality in GSD
patients is not entirely explained by the high rate of as-
sociated cancer deaths; thus, this high morbidity sub-
stantially affects the economy and public health [2].
Because of the Westernization of the Taiwanese diet and
environment, GSD is no longer rare among its Chinese
population and has become a major health problem [3].* Correspondence: ch2876@gmail.com
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reproduction in any medium, provided the orIn the absence of a suitable screening program for symp-
tomatic GSD, treating GSD and related complications
yields substantial healthcare costs.
The availability of ultrasonography as an accurate tool
for GSD diagnosis has facilitated evaluating GSD morbid-
ity by conducting epidemiological surveys of the general
population [2,4,5]. Previous research has explored the
prevalence of GSD and its associated factors [3]. Although
cross-sectional studies provide useful information regard-
ing disease prevalence, they fail to address the incidence
or new cases of GSD among the study population. Thus,
the population must be re-examined after a period of time
to determine the incidence and causal relations between
the risk factors and disease. From a preventive medicine
perspective, GSD prevention should focus the relevant risk
factors of the disease; thus, exploring the incidence and
risk factors of GSD is essential for preventing its develop-
ment and the cholecystectomy caused complications,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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indicated for estimating the incidence of GSD; we ex-
plored the incidence and risk factors of GSD in Taipei,
Taiwan, using a 5-year follow-up period and real-time ab-
dominal ultrasound data.
Methods
Data resource and data collection
Figure 1 shows the procedures for GSD screening be-
tween 2002 and 2007. We first established a study co-
hort to determine the incidence of GSD; the initial study
cohort comprised 2386 healthy adults (1235 males and
1151 females) who were voluntarily admitted to a teach-
ing hospital for a physical check-up between January
2002 and December 2002 in Northern Taiwan. Of the
2386 patients, 126 were diagnosed with GSD. The over-
all prevalence of GSD was 5.3%, comprising single stone
1.7% (n = 40), multiple stone 2.3% (n = 55), and chole-
cystectomy 1.3% (n = 31) [3]. The details of the study de-
sign and execution have been described in full elsewhere
[3]. Subsequent annual follow-up screenings for GSD
were conducted until 31 December, 2007 for the 2260
patients invited by telephone calls or invitation letters in
receive general health examinations and abdominal ex-
aminations who lacked GSD in 2002. Participants who
were diagnosed as GSD or known cholecystectomy for
GSD at the first screening were separately studied [6].
We analyzed all patients who participated in at least
two GSD screenings, but 964 (42.7%) failed to complete
the series of assessments. Those who lost to follow-up
during the 5-year period were older (50.9 ± 10.2 years2260 adults without 
GSD in 2002 invited a
screening between 2
and 2007
First round GSD screen




Figure 1 The procedure of screening for gallstone disease among heversus 45.1 ± 9.5 years, P < .0001), and exhibited higher
systolic blood pressure (SBP) levels (126.2 ± 20.4 mmHg
versus 119.0 ± 16.7 mmHg, P < .0001) and fasting plasma
glucose (FPG) levels (103.8 ± 23.0 mg/dL versus 95.7 ±
24.6 mg/dL, P < .0001) compared with the participants.
All procedures were performed in accordance with the
guidelines of the relevant institutional ethics committee,
adhering to the Declaration of Helsinki. The participant
information was anonymous and taken from the hospital
database. This access to personal records was approved
to use blood samples and ultrasound sonography results
and that these were collected as part of standard care by
the human subject review board of Cheng-Hsin General
Hospital (CHGH-IRB: (137)97-26) in Taipei, Taiwan.
Blood samples were collected and ultrasound sonog-
raphy was conducted. Clinical nurses drew fasting blood
samples from the study participants by using venipuncture.
Overnight-fasting serum and plasma samples (from whole
blood preserved using EDTA and NaF) were maintained
frozen at −20°C until analysis. We defined type-2 diabetes
(FPG ≥ 126 mg/dL) based on the 1997 ADA criteria [7],
using the following conditions: obesity as a body mass
index (BMI) ≥ 27 kg/m [2], high SBP ≥ 140 mmHg, high
diastolic blood pressure ≥ 90 mmHg, hypercholesterolemia
(≥200 mg/dL), hypertriglyceridemia (≥200 mg/dL), low HDL
(<35 mg/dL), high blood urea nitrogen (BUN; ≥ 20 mg/dL),
high creatinine (≥1.4 mg/dL), and hyperuricemia (≥7 mg/dL
for males or ≥ 6 mg/dL for females). Serum alanine trans-
aminase (ALT) or aspartate transaminase (AST) levels
of ≥ 40 U/L were classified as elevated [8]. In addition,









althy adults during 2002–2007.
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collected at one-to-one well-trained interviews using a
structured questionnaire.
Diagnosis of gallstone disease and nonalcoholic fatty
liver disease
After at least 8 hours of fasting, a panel of specialists exam-
ined the abdominal region of each patient, diagnosing GSD
based on real-time ultrasound sonography (TOSHIBA
nemio SSA-550A, Japan) and the presence of “movable
hyper-echoic foci with acoustic shadows.” Cases of GSD
were classified as follows: single gallbladder stone, mul-
tiple gallbladder stones, and cholecystectomy, excluding
gallbladder polyps. The cases were identified as any type
of GSD that developed among the study population [3].
The ultrasonographic criteria which were used to diag-
nose a fatty liver included liver and kidney echo discrepancy,
presence of an increased liver echogenicity, echo penetra-
tion into the deep portion of the liver, and clarity of the liver
blood vessel structures [9]. All study subjects who were di-
agnosed as nonalcoholic fatty liver disease (NAFLD) by
ultrasound and without disease history of Wilson’s disease,
intestinal bypass surgery, or gulten enteropathy, ingestion
of of drugs known to produce hepaticsteatosis including
methotrexate, tamoxifen, amiodarone, and nucleoside ana-
logues, positive serology for hepatitis B or C virus, a history
of another known liver disease, and alcohol consumption
(alcohol intake of 30 g/day or more for males and 20 g/day
or more for females) were enrolled the study [10].
Interobserver reliability in ultrasound sonography
To establish a consistent GSD diagnoses among the spe-
cialists, we used the Kappa statistic to assess the agree-
ment of interobserver reliability. We conducted a pilot
study, randomly selecting 100 non-study participants. Re-
garding interobserver reliability, the Kappa value for GSD
diagnosis among specialists was 0.79 (95% CI: 0.61–0.95)
[3]. In addition, the Kappa value for diagnosis of NAFLD
between specialists was 0.77 (95% CI: 0.69-0.88).
Statistical analysis
We performed statistical analyses using SAS for Windows,
(SAS version 9.0; SAS Institute Inc., Cary, NC, USA), de-
termining the GSD incidence per year based on the ratio
of the observed number of cases to the total number of
patient-years at risk. The 95% confidence intervals (95%
CI) were calculated for incidence by using a Poisson distri-
bution. Concerning the univariate analysis, a t-test and
chi-square test were used to evaluate the continuous and
categorical variables; a multiple Cox regression was con-
ducted to investigate the independence of factors asso-
ciated with developing GSD. A P value of < 0.05 was
considered statistically significant. The results are pre-
sented as mean ± SD.Results
Of the 2260 participants in the study cohort, 1296 attended
at least 2 sonographic check-ups: 710 (54.8%) attended 2
consultations, 402 (31.0%) attended 3 consultations, and
184 (14.2%) attended 4 or more consultations during the
5-year period. The overall response rate was approximately
57.3, and the mean follow-up time was 3.51 ± 0.84 years.
The patients were considered censored cases if their out-
comes were unavailable. Twenty participants were found
to have GSD (9 single stone and 11 multiple stones) and
three had received cholecystectomy for GSD during the 5-
year follow-up period. Table 1 shows that the females
attained higher attendance rates than the males did (62.3%
versus 52.8%) and young people (<40 and 40–49 years)
exhibited a slightly lower attendance rate compared with
other age groups.
Table 2 lists the gender- and age-specific incidences
of GSD. The overall incidence of GSD was 0.632% per
year (95% CI: 0.292%–2.009%), indicating a clear trend
based on age (p = 0.03), where values monotonically in-
crease. The values increased from 0.214% per year (95%
CI: 0.062%–1.719%) at ages <40 to 0.470% per year
(95% CI: 0.112%–2.103) at ages 40–49, 0.585% per year
(95% CI: 0.236%–1.983%) at ages 50–59, and 1.394% per
year (95% CI: 0.410–2.477%) at ages greater than 60. The
age groups exhibited no consistent patterns. Females
demonstrated a slightly higher incidence (0.741% versus
0.496% per year, P = 0.40) compared with males, but the
gender difference was non-significant.
Table 3 shows the risk factors for developing GSD
based on the univariate analysis. The significant risk fac-
tors of GSD were age (P < .0001), FPG (P < .0001), SBP
(P < .0001), BMI (P < .0001), ALT (P = .001), and NAFLD
(P = .04). In addition, to assess how these factors inde-
pendently contributed to GSD, the significant variables
from the univariate analysis were examined using a Cox
regression, evaluating age, FPG, SBP, BMI, ALT, and
NAFLD. As Table 4 shows, subsequent to adjustment for
confounders, the following factors appeared to be signifi-
cantly related to GSD incidence: age (50–59 years versus
< 40 years, RR = 2.16 [95% CI: 1.09–5.97], 60+ years ver-
sus < 40 years, RR = 3.81 [95% CI: 2.77–8.63]), elevated
BMI (≥27 kg/m2 versus < 24 kg/m2, RR = 1.64 [95% CI:
1.07–2.98]), elevated FPG (≥126 mg/ dL versus <110 mg/
dL, RR = 1.68, 95% CI: 1.10–3.87), and NAFLD(yes versus
no, RR = 1.44, 95% CI: 1.21–1.90).
Discussion
Incidence and risk factors for the development of
gallstone disease
Knowledge of GSD epidemiology is crucial to managing
this disorder when planning preventive programs and
identifying the optimal therapeutic strategies [2]. Previous
clinical studies have yielded reliable positive (0.99–1.00)
Table 1 The attendance rate of gallstone disease









Male 1176 621 52.8
Female 1084 675 62.3
Age
<40 734 373 50.8
40-49 704 409 58.1
50-59 464 285 61.4
60+ 358 229 64.0
Total 2260 1296 57.3
Chen et al. BMC Gastroenterology 2014, 14:83 Page 4 of 7
http://www.biomedcentral.com/1471-230X/14/83and negative (0.90–0.96) predictive values regarding the
diagnostic efficacy of ultrasonography [11], suggesting that
abdominal ultrasound is a robust method for GSD screen-
ing. The availability of ultrasonography as an accurate tool
for GSD diagnosis has facilitated evaluating GSD morbid-
ity by conducting epidemiological surveys of study popula-
tions in Eastern and Western countries [2,3,12,13]. Few
studies have explored the incidence and possible etiology
of GSD among the general population of Taiwan.
The incidence of GSD appears to vary among test popu-
lations and differs among studies conducted in disparate
countries [2,12,13]. It is of interest that the prevalence and
the incidence differ very little from two Italian studies,
10 years apart - GREPCO (1998) and MICOL (2008)
[2,13]. This may suggest that the diet of the Chinese in
Taiwan is already Westernised. In addition to varying
methods of assessing GSD, this disparity might be caused
by differences among genetic populations. In this study, theTable 2 Sex- and age-specific incidence of gallstone disease a
Incidence of any g











Total 1296 23annual incidence of overall GSD was slightly lower com-
pared with that of other evidence-based studies [2,13]; this
difference may be a result of the Kappa value for the agree-
ment of interobserver reliability. Although the value ap-
peared appropriate [14], non-differential misclassification-
bias identification could have occurred, generating an
underestimated GSD incidence.
In this study, the proportion of the population lost to
follow up was in the higher risk categories for GSD. This
deficiency is likely to have under recorded the overall inci-
dence. In addition, the response rate was lower than that
reported in other follow-up studies for GSD [2,12,13] and
the older population had a higher attendance rate could
be related a potential self-selection bias. The characteris-
tics of the elderly subjects which may cause them to select
themselves in the screening program create abnormal or
undesirable conditions in the group.
The estimated incidence of GSD in this study was
higher in females compared with males, and increased
as age increased. This finding is consistent with the re-
ports of other studies conducted elsewhere [2,13]. GSD
is rare in neonates and young children [5]; thus, long-
term exposure to risk factors may explain the increased
probability of developing GSD in old age. The morbidity
of GSD increases as age increases, noticeably elevating
after age 40 and becoming 4- to 10-fold more likely [15].
Although GSD patients are often clinically silent, the
symptoms of GSD and number of severe complications
increase as age increases, leading to cholecystectomy in
more than 40% of patients older than 40 [5,16]. In
addition, gender is a substantial factor in GSD and fe-
males are almost twice as likely as males to develop
stones [15]. Female sex hormones adversely influence
hepatic bile secretion and gallbladder function and estro-
gens increase cholesterol secretion and diminish bile salt
secretion [5]. Thus, females do not have a significantlymong screened patients (n = 1296)
allstone disease










Table 3 Univariate analysis of risk factors for the development of gallstone disease among screened patients (n = 1296)
Development of gallstone disease
Variables Yes (n = 23) No (n = 1273) P value for t test or chi-square test Definitions of disease condition
Mean ± SD Mean ± SD
Continuous variables
Age (years) 60.55 ± 14.28 51.32 ± 13.01 <0.0001 ----
Fasting plasma glucose (mg/dL) 113.78 ± 20.69 100.55 ± 30.06 <0.0001 ≥126 mg/dL
Systolic blood pressure (mmHg) 132.90 ± 19.77 123.08 ± 18.69 <0.0001 ≥140 mmHg
Diastolic blood pressure (mmHg) 80.77 ± 11.90 79.23 ± 12.07 NS ≥90 mmHg
Body mass index (Kg/m2) 24.86 ± 3.48 23.39 ± 3.37 <0.0001 ≥27Kg/m2
Total cholesterol (mg/dL) 218.17 ± 35.68 209.80 ± 36.75 NS ≥200 mg/dL
Triglyceride (mg/dL) 150.68 ± 88.04 147.26 ± 79.53 NS ≥200 mg/dL
HDL (mg/dL) 55.70 ± 16.31 54.24 ± 15.92 NS <35 mg/dL
BUN (mg/dL) 14.82 ± 6.19 14.57 ± 5.80 NS ≥20 mg/dL
Creatinine (mg/dL) 1.07 ± 0.33 1.05 ± 0.28 NS ≥1.4 mg/dL
AST (U/L) 30.78 ± 19.61 27.08 ± 18.55 NS ≥40U/L
ALT (U/L) 34.42 ± 22.06 28.19 ± 21.50 0.001 ≥40U/L
Uric acid (mg/dL) 6.05 ± 1.01 5.99 ± 1.12 NS ≥7 mg/dL for males or ≥6 mg/dL for
females
Categorical variables
NAFLD yes 17 (73.9%) 672 (52.8%) 0.04 ----
no 6 (26.1%) 601 (47.2%) ----
Heavy fatty or fried foods yes 5 (21.7%) 251 (19.7%) NS ----
no 18 (78.3%) 1022 (80.3%) ----
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Another possible reason was that a Type II error due to
small incident numbers, since the relative risk is 2.12 in
this study. Previous research has shown that cholesterol
GSD is common among Western populations, whereasTable 4 Cox regression model of risk factors associated
with the development of gallstone disease among
screened patients (n = 1296)
Development of gallstone
disease (yes versus no)
Variables Relative risk (95% CI)
Gender (female versus male) 2.12 0.45-4.16
Age (40–49 versus <40 years) 1.65 0.41-3.79
(50–59 versus <40 years) 2.16 1.09-5.97
(60+ versus <40 years) 3.81 2.77-8.63
BMI (24–27 versus <24 Kg/m2) 1.13 0.56-3.28
(≥27 versus <24 Kg/m2) 1.64 1.07-2.98
FPG (110–125 versus <110 mg/dL) 1.22 0.49-2.31
(≥126 versus <110 mg/dL) 1.68 1.10-3.87
Higher SBP (yes versus no) 1.11 0.53-2.18
Higher ALT (yes versus no) 1.03 0.68-2.87
NAFLD (yes versus no) 1.44 1.21-1.90pigment GSD is common in Taiwan [17]. The differing
findings among Eastern and Western populations suggests
that cholesterol GSD is not yet a major problem among
Chinese populations.
The findings indicated that FPG ≥ 126 mg/dL was highly
associated with GSD incidence; that is, type 2 diabetes
might be a positive risk factor for GSD. The association be-
tween diabetes mellitus and GSD is confounded by age,
obesity, and family history of GSD [15]. The possible patho-
genic reasons for this are that type 2 diabetes combined
with GSD might induce acute cholecystitis more often and
yield a higher probability of progression to septicemia com-
pared with non-diabetic patients, who exhibit normally
functioning gallbladders. Late-onset diabetes patients may
demonstrate a higher lithogenic bile index compared with
non-diabetics after adjusting for sex and age [18]. The asso-
ciation between diabetes and GSD is stronger among pa-
tients who have a history of treated diabetes mellitus than it
is among those with a simple history of diabetes; this could
indicate that hyperglycemia affects gallbladder motility [3].
In addition, the links among diabetes, obesity, and GSD
most likely originate from metabolic syndrome [15,19].
After using univariate and multiple Cox regression
analyses, the findings indicate that obesity is a significant
risk factor for GSD. This agreed with the results of other
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[2,12,13]. The validity of BMI as a measure of adiposity
has been assessed by comparison with densitometry [12].
From a biological viewpoint, BMI is primarily a surrogate
of lean body mass when BMI and height-adjusted waist
circumference are included in the same model, because
the variation in BMI attributable to adiposity is essentially
controlled by the height-adjusted waist circumference
variable [12,18]. However, additional epidemiological and
etiologic investigations must explore the pathophysio-
logical mechanisms among BMI, waist circumference, and
GSD among Chinese populations.
Cirrhosis is a predictive risk factor for GSD, particu-
larly in the advanced stages of the disease [20,21]. The
annual incidence of GSD among cirrhosis patients is ap-
proximately 8 times higher than is that among the gen-
eral population [20]. ALT has, for some time, been
viewed as a sensitive indicator of liver-cell injury [22].
Determining serum ALT levels is the most frequent test
used to identify liver disease. This parameter also acts as
a surrogate marker for disease severity and an index of
hepatic activity [18]. In addition to type 2 diabetes, the
findings show that elevated ALT levels may indicate an
increased risk of GSD, implying that appropriately inte-
grated diagnosis and therapy in the early stages of liver
dysfunction might facilitate preventing GSD. Additional
studies should be conducted to explore whether elevated
ALT levels are an indicator of GSD, rather than a sign of
serious liver diseases, such as cirrhosis, because they can
indicate a fatty liver (and thus a high BMI) and the early
stages of chronic liver disease [18].
NAFLD includes a wide spectrum of liver diseases,
ranging from simple fatty liver, simple steatosis, nonalco-
holic steatohepatitis (NASH), and liver cirrhosis, which
may eventually progress to liver damage, liver fibrosis,
portal hypertension, and hepatocellular carcinoma [23].
In mainland China and Taiwan, NAFLD is now viewed
as one of major causes of asymptomatic elevation of
liver enzymes [24,25]. Our results indicated that NAFLD
was associated with incident GSD after adjustment for
confounding factors.The association between NAFLD
and GSD is based upon associated risk factors and meta-
bolic derangements that are common to both conditions.
From the preventive medicine viewpoint, modifiable risk
factors for GSD and NAFLD include obesity and meta-
bolic syndrome, both of which can be addressed with
weight loss, exercise and dietary modifications such as a
low-fat, low-sugar diet [26].
Methodological considerations
Although we used a follow-up study design to clarify the
temporal characteristics of the potential risk factors of
GSD, certain limitations apply to this study. First, a
major limitation was the potential self-selection biascaused by the hospital-based study design and those
aged 60 or over were only 18% of the sample and yet de-
veloped 48% of the GSD; that is, the sample may not be
representative of the general population. Second, the risk
characteristics pertinent to the study participants signifi-
cantly differed from those of non-respondents, indicat-
ing that the patients who did not complete the follow-up
might have severe GSD. We assumed that all new GSD
cases occurred during screening year; however, because
additional GSD cases could occur at any time during the
screening period, the incidence of GSD could be under-
estimated. Third, we did estimate the incidence of GSD
formation, but rather investigated the incidence of newly
screened GSD, focusing only on clinically relevant GSD.
Fourth, we did not distinguish between cholesterol and
pigment stones, potentially yielding measurement errors
and distinct pathogenicity. Fifth, the incidence of GSD
was higher (although non-significant) in female, how-
ever, there are no data regarding the number of pregnan-
cies and the frequency of pill in this study. Finally, we
further explored the 964 out of 2260 subjects who were
lost to follow-up using telephone interview: 29 cases de-
ceased, 106 cases moved out of the study township, 281
cases were refusals, 12 cases had presence of GSD or
history of cholecystectomy. This might imply that the
sample size was insufficient to estimate how potential
risk factors affect the incidence of GSD. Further long-
term research should be conducted to explore the mor-
bidity of GSD and plausible biological mechanisms
underlying its development.
Conclusion
Increased age is a well-established risk factor for the de-
velopment of GSD. The current findings indicate that
high BMI, elevated FPG and NAFLD levels are also asso-
ciated with GSD.
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